Company news

ImmuneOnco won the project supported by Science and Technology Commission of Shanghai Municipality.

2017-6-7 0:00:00Click:543

On June 7, 2017, ImmuneOnco Biopharmaceuticals Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, announced that,one of its research projects won the supportion by Shanghai small and medium-sized enterprise science and technology project; the project No.: 17CT24H8200.

 “The Bi-functional protein simultaneously targeting CD20/CD47 is one of many exciting programs in our preclinical development portfolio," said Dr. Wenzhi Tian, Chairman and Chief Executive Officer of ImmuneOnco. "

  Binding to CD20 on the surface of lymphoma cell membrane can kill tumor cells through ADCC and CDC pathway; Binding to CD47 makes tumor cell expose to the immune attack activated by the same protein blocking the SIRPa signals. We plan to file the IND of our novel bi-functional protein as early as possible." In preclinical studies, the combined inhibition of CD20 and SIRPa has resulted in significant anti-tumor activity in a variety of xenograft models.

    Patent application number in China: 201710151979.6; the title: new recombinant bifunctional fusion protein, its preparation method and application; the inventor: ImmuneOnco Biopharmaceuticals Co., Ltd.